

Press release

Lund, October 4, 2021
EQL Pharma AB (publ)
556713-3425

EQL PHARMA

Latanoprost EQL Pharma Approved

The pharmaceutical Latanoprost EQL Pharma, eye drops 50 micrograms/ml, has been approved for sale in Sweden, Denmark and Norway.

Latanoprost EQL Pharma is by prescription-only and is used in the treatment of glaucoma in children and adults. It works by lowering the increased pressure that this disease causes in the eye.

Latanoprost EQL Pharma has a planned launch date in the company's first financial quarter (April-June) next year. The Scandinavian market for Latanoprost currently has sales of approximately SEK 50m and has between two and five active competitors per country.

For further information, please contact:

Christer Fåhraeus

CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.